Navelbine (Vinorelbine)

Vinorelbine interferes with microtubule assembly by binding to tubulin, preventing polymerisation during mitosis. This blockade halts cell division at the M phase, leading to apoptosis of rapidly proliferating cancer cells, which underlies its therapeutic effect in solid tumours.

The exact dose of Navelbine is determined by the prescribing oncologist based on individual factors such as body surface area, disease stage, and concurrent therapies. No standardized regimen can be provided here; dosing must follow the clinician’s assessment.

Safety of vinorelbine in pregnancy and lactation has not been established. It is generally contraindicated because of potential fetal toxicity. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative options with their healthcare provider.

To request Navelbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Vinorelbine belongs to the Vinca alkaloid class, offering a distinct mechanism from taxanes such as docetaxel. Compared with taxanes, vinorelbine often shows a different toxicity profile, with less severe alopecia but a higher incidence of neutropenia. Choice of therapy depends on tumour characteristics, prior treatment, and patient tolerance.

Navelbine should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight. Do not refrigerate or freeze unless the label specifically indicates otherwise.

Navelbine is administered orally. The tablet (or capsule) should be swallowed whole with a glass of water, preferably on an empty stomach or as directed by the prescriber. Anti‑emetic medication may be given concurrently to reduce nausea.

The most critical risks include severe neutropenia leading to infection, febrile neutropenia, pulmonary toxicity such as interstitial pneumonitis, and rare but life‑threatening allergic reactions. Patients should be monitored closely for signs of infection, respiratory distress, or hypersensitivity.

Navelbine is contraindicated in patients with known hypersensitivity to vinorelbine or other Vinca alkaloids, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment. Caution is also advised for individuals with pre‑existing peripheral neuropathy or cardiac arrhythmias.